Skip to main content

Table 3 Secondary outcome measures

From: Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover study

Change in total exercise time during sequential exercise tolerance testing performed over a 6-week study period
Change in time to 0.1 mV ST-segment depression during sequential exercise tolerance testing performed over a 6-week study period
Change in time to maximum ST-segment depression during sequential exercise tolerance testing performed over a 6-week study period
Change in recovery time to 0.05 mV ST-segment depression during sequential exercise tolerance testing performed over a 6-week study period
Evidence of hypoglycaemia through twice-daily home blood glucose monitoring and once-weekly random serum glucose measurements
Evidence of renal dysfunction through once-weekly monitoring of serum creatinine, electrolytes and estimated glomerular filtration rate
Evidence of acute pancreatitis through once weekly monitoring of serum amylase alongside telephone and once-weekly face-to-face study visits